Shoulder Innovations (SI) has wrapped up FY 2025 with Q4 revenue of US$14.4 million and a basic EPS loss of US$0.38, capping off a twelve month stretch where revenue reached US$47.3 million and basic EPS over the trailing period came in at a loss of US$4.65. The company has seen quarterly revenue move from US$8.7 million in Q4 2024 to US$14.4 million in Q4 2025, while quarterly basic EPS losses shifted from US$45.21 in Q4 2024 to US$0.38 in Q4 2025, creating a picture in which strong top line momentum contrasts with margins that are still under pressure.
See our full analysis for Shoulder Innovations.With the latest numbers on the table, the next step is to see how this mix of rapid revenue growth and ongoing losses compares with the key narratives investors have been leaning on so far.
See what the community is saying about Shoulder Innovations
49.6% revenue growth, but losses TTM of US$40.4 million
- Over the last twelve months, Shoulder Innovations generated US$47.3 million of revenue and recorded a net loss of US$40.4 million, with trailing basic EPS at a loss of US$4.65.
- Analysts' bullish view leans on that 49.6% revenue growth and expectations for roughly 25.3% annual revenue growth, yet the ongoing losses mean the company is still in investment mode, which
- supports the growth angle by showing sales expanding while forecasts call for above market revenue growth, and
- keeps the bullish case exposed to the fact that profitability has not been achieved over the trailing twelve months and is not forecast within the next three years.
Bulls argue this kind of growth in a focused niche could be early stage rather than late cycle. That is where the detailed market narrative for Shoulder Innovations comes in, especially if you want to see how growth, margins and scale-up plans fit together over several years. 🐂 Shoulder Innovations Bull Case
Quarterly net loss widened from US$4.1 million to US$8.7 million
- Within the reported periods, net loss moved from US$4.1 million in Q4 2024 to US$8.7 million in Q3 2025, alongside quarterly revenue rising from US$8.7 million to US$11.8 million over those same points.
- Skeptics highlight that expenses such as SG&A and legal costs have risen faster than revenue at times, and that view
- lines up with the widening net loss across several quarters even as revenue stepped up from US$7.5 million in Q3 2024 to US$14.4 million in Q4 2025, and
- frames the risk that if higher spending on sales coverage and intellectual property protection does not translate into better margins, the company may keep reporting sizeable losses despite higher sales.
Bears point to that pattern as a sign that legal and commercial spending could weigh on earnings for longer. This is why a closer look at the full cautious narrative can help you judge how serious those pressures might be. 🐻 Shoulder Innovations Bear Case
P/S of 6.1x sits between peers and wider industry
- Shoulder Innovations trades on a P/S of 6.1x, compared with a peer average of 10x and a broader US Medical Equipment industry average of 2.8x, alongside a current share price of US$14.01 and an analyst median price target of US$21.00.
- Analysts' consensus view suggests the company is being treated as a higher growth name within its industry, and that stance
- is reflected in the higher P/S than the wider medical equipment group even though the company is still loss making, and
- is balanced by the lower P/S versus the peer set plus the 49.9% implied upside from US$14.01 to the US$21.00 target, which investors can weigh against the fact that profitability is not expected within the next three years.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Shoulder Innovations on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If this mix of growth and ongoing losses feels finely balanced, now is a good time to check the full picture for yourself and weigh both sides. To see how that tension between risks and rewards stacks up in detail, take a look at the 3 key rewards and 1 important warning sign.
Explore Alternatives
Shoulder Innovations is still recording sizeable losses despite 49.6% revenue growth, with expenses and legal costs pressing on margins and profitability timelines.
If those ongoing losses and margin pressures make you want a steadier profile, take a look at our 67 resilient stocks with low risk scores that focuses on companies with more resilient risk scores and potentially smoother earnings paths.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com